Apogee Therapeutics Q2 net loss $18.9M; $345M IPO funds runway into 4Q26

Apogee Therapeutics, Inc.

2023-Q2 EPS reported -$6.28

Raised $345M in upsized July IPO; cash balance $125.1M at June 30; projected runway into 4Q 2026.
Phase 1 trial of APG777 initiated; initial safety/PK data expected mid-2024.
Appointed Mark McKenna Chairman, Matt Batters General Counsel, Rebecca Dabora CTO.
Net loss Q2 2023 $18.9M vs $1.8M in Q2 2022; R&D expenses rose to $13.9M.
APG808 development candidate selected expected Q4 2023; APG990 candidate in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apogee Therapeutics, Inc. reported financial results for second quarter 2023.

Period: second quarter 2023
Result: reported results

Exact text from the filing

On August 28, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-095577

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.